Long-term daclizumab therapy for the treatment of noninfectious ocular inflammatory disease

Canadian Journal of Ophthalmology

Volumn 46, Issue 4, 2011, Pages 322-328

  Wroblewski, Keith ^a,b   Sen, H Nida ^a   Yeh, Steven ^a   Faia, Lisa ^a   Li, Zhuging ^a   Sran, Pushpa ^a   Gangaputra, Sapna ^a   Vitale, Susan ^a   Sherry, Patti ^a   Nussenblatt, Robert ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DACLIZUMAB;

ABDOMINAL CRAMP; ADULT; ARTICLE; CLINICAL ARTICLE; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ECZEMA; EYE INFLAMMATION; FEMALE; FIBROSIS; FOLLICULITIS; GASTROINTESTINAL INFECTION; HERPES ZOSTER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEG EDEMA; LETHARGY; LIVER FUNCTION TEST; LONG TERM CARE; LYMPHADENOPATHY; MALE; NEURALGIA; PSORIASIS; RASH; RETROSPECTIVE STUDY; SIDE EFFECT; SKIN INFECTION; SKIN MANIFESTATION; UPPER RESPIRATORY TRACT INFECTION; VISUAL ACUITY;

EID: 84455208649     PISSN: 00084182     EISSN: 17153360     Source Type: Journal    
DOI: 10.1016/j.jcjo.2011.06.008     Document Type: Article

References (27)

1. Galor A, Jabs DA Leder HA, et al. Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation. Ophthalmology. 2008;115:1826-32.
2. Kempen JH, Gangaputra S, Ebenezer D, et al. Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment. Am J Ophthal. 2008;146:802-12.
3. Madigan WP, Raymond WR, Wroblewski KJ, et al. A review of pediatric uveitis: Part II autoimmune diseases and treatment modalities. J Pediatr Ophthal Strabismus. 2008;45:2002-19.
4. Lyon F, Gale RP, Lightman S. Recent developments in the treatment of uveitis: an update. Expert Opin Investig Drugs. 2009;18:609-16.
5. Itty S, Pulido JS. Rituximab for intraocular lymphoma. Retina. 2009; 29:129-32.
6. Taylor SR, Salama AD, Joshi L, Pusey CD, Lightman SL. Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis. Arthritis Rheum. 2009;60:1540-7.
7. Sharma SM, Nestel AR, Lee RW, Dick AD. Clinical review: anti-TNF alpha therapies in uveitis: perspective on 5 years of clinical experience. Ocul Immunol Inflamm. 2009;17:403-14.
8. Stone JH, Holbrook JT, Marriott MA, et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Wegener's Granulomatosis Etanercept Trial Research Group. Arthritis Rheum. 2006;54:1608-18.
9. Ramos-Casals M, Roberto-Perez-Alvarez, Diaz-Lagares C, Cuadrado MJ, Khamashta MA; BIOGEAS Study Group.Autoimmune diseases induced by biological agents: a double-edged sword? Autoimmun Rev. 2010;9:188-93.
10. Waldman TA. Anti-Tac (daclizumab) in the treatment of leukemia, autoimmune diseases and in the prevention of allograft rejection: a 25 year personal odyssey. J Clin Immunol. 2007;27:1-18.
11. Jabs DA, Nussenblatt RB, Rosenbaum JT; Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of First International Workshop. Am J Ophthal. 2005;140:509-16. (Pubitemid 41224845)
12. Buggage RR, Levy-Clarke G, Sen HN, et al. A double masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behcet's disease. Ocul Immunol Inflamm. 2007;15:63-70. (Pubitemid 46897689)
13. Nazemzadeh M, Faia L, Shah R, et al. Daclizumab and its effect on chronic uveitic CME. Investig Ophthal Vis Sci. 2009;50:2683.
14. Faia LJ, Wroblewski KJ, Yeh S, et al. Dermatologic Manifestations of Daclizumab for Ocular Inflammatory Disease. Investig Ophthal Vis Sci. 2008;49:4725.
15. Wroblewski KJH, Sen HN, Yeh S. Combination daclizumab and sirolimus therapy for the induction of immune tolerance in non-infectious intermediate and posterior uveitis. Association for Research in Vision and Ophthalmology Annual Meeting, Fort Lauderdale, Florida, May 2009.
16. Nussenblatt RB, Fortin E, Schiffman R, et al. Treatment on noninfectious intermediate and posterior uveitis with humanized anti-Tax mAb: a phase 1/II clinical trial. Proc Natl Acad Sci U S A. 1999;96:7462-6. (Pubitemid 29299684)
17. Nussenblatt RB, Thompson DJ, Li Z, et al. Humanized anti-interleukin- 2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration. J Autoimmun. 2003;21:283-91.
18. Nussenblatt RB, Peterson JS, Foster CF, et al. Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis. Ophthalmology. 2005;112:764-70.
19. Buggage RR, Levy-Clarke G, Sen HN, et al. A double masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behecet's disease. Ocul Immunol Inflamm. 2007;15:63-70. (Pubitemid 46897689)
20. Yeh S, Wroblewski K, Buggage R, et al. High dose daclizumab for the treatment on non-infectious intermediate and posterior uveitis. J Autoimmun. 2008;31:91-7.
21. Sobrin L, Huang JJ, Christen W, et al. Daclizumab for the treatment of birdshot chorioretinopathy. Arch Ophthal. 2008;126:186-91.
22. Bhat P, Castaneda-Cervantes RA, Doctor PP, Foster CS. Intravenous daclizumab for recalcitrant ocular inflammatory disease. Graefes Arch Clin Exp Ophthalmol. 2009;247:687-92.
23. Blohme I, Larko O. Skin lesions in renal transplant patients after 10 to 23 years of immunosuppressive therapy. Acta Derm Venereol. 1990;70: 491-4. (Pubitemid 20365170)
24. Anderson LA, Gadalla S, Morton LM, et al. Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies. Int J Cancer. 2009;125:398-405.
25. Nussenblatt RB, Thompson DJS, Li Z, et al. Humanized anti-interleukin 2(IL-2) receptor alpha therapy long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration. J Autoimmun. 2003;21:283-93. (Pubitemid 37410117)
26. Sen HN Levy-Clarke G, Faia LJ, et al. High-dose daclizumab for the treatment of juvenile idiopathic arthritis-associated active anterior uveitis. Am J Ophthalmol. 2009;148:696-703.
27. Imrie FR, Dick AD. Biologics in the treatment of uveitis. Curr Opin Ophthalmol. 2007;18:481-6. (Pubitemid 351339402)